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Background: Schizophrenia is a severe neuropsychiatric disorder thought to result from abnormal brain
development. Nogo, an oligodendrocyte bound molecule, signals by binding to the Nogo receptor (NgR) located
on axonal membranes. The NgR co-receptors include p75 neurotrophin receptor or TNF receptor orphan Y
(TROY). Nogo signaling is responsible for central nervous system myelin regulation and neurite outgrowth
during neurodevelopment, and plasticity in the mature brain.
Methods: We examined single nucleotide polymorphisms (SNPs) in NgR, p75, and TROY receptor genes and
downstream signaling partner With No Lysine (K) (WNK1) andMyelin transcription factor 1-like (Myt1l) genes
in an Australian case–control schizophrenia cohort (n=268/group). High-throughput SNP genotyping was per-
formed using the MassARRAY® genotyping assay.
Results: Analysis revealed a signiﬁcant association between theMyt1l SNP rs2304008 and female schizophrenia
subjects. The WNK1 SNP rs1468326 and the Myt1l SNP rs3748988 showed signiﬁcant associations with
schizophrenia in subjects with a maternal mental history and in subjects who experienced childhood trauma
respectively. Following Bonferroni correction, all signiﬁcance was lost.
Conclusions: Despite the lack of positive ﬁndings in our population after correction for multiple testing, previous
gene expression and association studies in schizophrenia suggest the implication ofNgR signaling pathway genes
in the etiology of schizophrenia remains topical and timely.
General signiﬁcance: Further investigations will be necessary to fully assess the role of these genes in the patho-
physiology of schizophrenia. However these genesmay prove useful in further understanding themechanism by
which negative experiences early in life can affect myelin-related processes in the context of schizophrenia.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophrenia is a severe neuropsychiatric disorder with an elusive
etiology, thought to result from abnormal brain development. Receptor/
ligand interactions on oligodendrocytes are critically involved in axonal
outgrowth processes which are key to normal brain development [1].
Inappropriate outgrowth and myelination of axons could subsequently
result in axonal miswiring which has been previously reported in
schizophrenia and in childrenwho have experienced stress and trauma
early in life [2,3]. In normal brain development, oligodendrocytesal Research Institute, University
SW, Australia. Tel.: +61 2 4221
s), fernande@uow.edu.au
. This is an open access article underare responsible for regulating axonal growth via the Nogo protein and
its receptor, Nogo receptor (NgR). Nogo binds to the leucine-rich repeat
(LRR) domains of NgR and facilitates the inhibition of axon growth [4].
There are a number of co-receptors that signal with NgR on the axonal
membrane including Lingo-1 as a co-factor [5–7]. Since NgR itself
does not contain a transmembrane domain, it requires a transmem-
brane co-receptor in order to elicit intracellular signals. NgR contains a
glycosylphosphatidylinositol-anchored-ligand-binding subunit which
binds with either the p75 neurotrophin receptor or Tumor necrosis fac-
tor Receptor Orphan Y (TROY). The resulting trimolecular NgR receptor
complex activates RhoA a small GTP-binding protein, subsequently
setting off a cascade of intracellular molecular events resulting in the
collapse of growth cones, thus preventing further growth by the axon,
and the inhibition of myelination [4,8].
Many genes have been tested for their implication in the genetic
susceptibility for schizophrenia over the last 2 decades; however
no studies have found a single gene unambiguously linked to dys-
function leading to schizophrenia. Genotyping of single nucleotidethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Subject Demographics for Control (n= 268) and Schizophrenia Subjects (n= 268).
Control
subjects n (%)
Schizophrenia
subjects n (%)
Gender
Female 99 (37%) 82 (30.6%)
Male 169 (63%) 186 (69.4%)
Age at assessment (years)
Female 32.19 40.48
Male 42.22 38.14
Family history of mental disorders
Mother 41 (15.3%) 95 (35.5%)
Father 49 (18.3%) 106 (39.6%)
Traumatic childhood experience 60 (22.4%) 110 (41.0%)
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measure genetic variation between members of a species. SNPs are
deﬁned as the change in a single base pair, or a point mutationwithin
a DNA strand, occurring in both coding and non-coding regions of the
genome; they are the most frequently occurring type of genetic var-
iation, accounting for 90–95% of DNA sequence variation within a
population.
Numerous human genetic linkage studies, examining the tendency
of certain genes (or loci, the location of the genes on the chromosome)
to be inherited together in patient families, and association studies
which measure the concurrence of genetic markers (e.g. insertions/
deletions, microsatellites, and SNPs) with a particular phenotype,
suggest a link between Nogo signaling and schizophrenia [6,9,10].
Functional genetic polymorphisms in the NgR gene previously associated
with schizophrenia have been reported to directly affect the interactions
between NgR and its co-receptors p75 and TROY in in vitro neuronal
culture [6,9]. Patients with 22q11 deletion syndrome (including the
NgR gene locus) showed schizophrenia related endophenotypes includ-
ing impaired working memory, impaired prepulse inhibition and other
cognitive dysfunctions [11–13]. An increase in the levels of the Nogo
ligand mRNA has also been reported in schizophrenia patients,
supporting the hypothesis that the stimulation of NgR may be altered
in schizophrenia [14]. However, little is known regarding the genetic
implication ofNgR co-receptors p75 and TROY in the genetic susceptibil-
ity of schizophrenia.
Interestingly, downstreamsignalingpartners of NgRpathways,With
No Lysine (K) (WNK1) and Myelin transcription factor 1-like (Myt1l)
have also been found to be altered in schizophrenia patients compared
to controls at the genetic level.WNK1 gene expression has been consis-
tently reported to be upregulated in the prefrontal cortex of schizophre-
nia sufferers in genomewide association studies [13,15], suggesting that
it plays a signiﬁcant role in this disorder. In addition, a copy number var-
iation meta-analysis study revealed that microduplications disrupting
the Myt1l gene are associated with schizophrenia, in particular
childhood-onset schizophrenia, a rare and more severe form of this
devastating disorder [16]. Furthermore, signiﬁcant genetic associations
have also been reported between polymorphisms in the Myt1l
gene and schizophrenia in a Chinese population [17], conﬁrming the
potential of Myt1l to be involved in the genetic susceptibility of
schizophrenia. However to date, no case–control genetic association
for either Myt1l or WNK1 genes has been tested in a Caucasian
schizophrenia population.
Early life neglect has been shown to disrupt the translation of
myelin-related genes in a mouse model of childhood neglect [18].
Additionally, early traumatic experiences including neglect, physical
abuse, sexual abuse, post-traumatic stress disorder, and psychiatric
illness, have been shown to be signiﬁcantly associated with a decrease
in the size of the highly myelinated corpus callosum [19]. Considering
the role of NgR signaling in myelin-related processes it could be specu-
lated that these pathwaysmay also be playing a role in the neurobiolog-
ical processes occurring during childhood, the critical period of brain
development. Furthermore due to adolescence also being a critical
period for the development of schizophrenia and the known implica-
tions of NgR signaling in schizophrenia, we hypothesized that NgR
signaling may play an underlying role in the implication of childhood
maltreatment with incidence of psychiatric disorders including
schizophrenia.
Due to the implication of the NgR complex in neurite outgrowth and
myelination processes throughout neurodevelopment, as well as the
genetic implication of NgR, WNK1 and Myt1l in schizophrenia suscepti-
bility, we sought to examine several SNPs of interest within NgR signal-
ing pathways in a selected case–control schizophrenia population,
factoring in early life stresses such ashaving a parental history ofmental
illness or other traumatic events, to assess if genetic abnormalitieswith-
in these genes may have an association with early life adversity and
schizophrenia.2. Materials and methods
2.1. DNA samples
DNA samples were obtained from the Australian Schizophrenia
Research Bank (ASRB). Subjects with schizophrenia were identiﬁed
using theDiagnostic and StatisticalManual ofMental Disorders-IV criteria.
In addition, all participants were subjected to thorough psychometric
testing to assess the extent of psychiatric illness in our schizophrenia
population, in addition to excluding the presence of mental disorders
in our control group. The battery of psychometric testing included: the
Psychosis Screener (from the Western Australian Family Study of
Schizophrenia), the Diagnostic Interview for Psychosis (ASRBmodiﬁca-
tion [20]), the Scale for the Assessment of Negative Symptoms (SANS),
the General Assessment of Functioning Scale (GAF), the International
Personality Disorder Examination Screening Questionnaire (ICD-10
Module), the Childhood Adversity Questionnaire, and the Schizotypal
Personality Questionnaire (SPQ). Subjects were matched for gender
and age and all samples were from Caucasian volunteers. The ethnic
origin of the Caucasian volunteers was determined by the participant's
response to questions regarding their birth place, in addition to the
birth place of their family members 2 generations before them on
both maternal and paternal sides of the family. Of the 536 subjects in
this study 458 (85.4%) were born in Australia or New Zealand, 43
(8.0%) were born in the United Kingdom, and 12 (2.2%) were born in
the United States or Canada; the remaining 23 (4.4%) were born in
Europe. All subjectswere of (self-reported) Europeandescent. The com-
plete sample consisted of 268 schizophrenia cases, composed of 186
males and 82 females, with an average age of 38.86 years (males:
38.14 years, females: 40.48 years); and 268 matched controls, com-
posed of 169 males and 99 females, with an average age of 38.56
years (males: 42.22 years, females: 32.19 years), with no prior history
of mental disorders (Table 1). While the sample size of this cohort
may seem somewhat limited for a case–control study, it must be noted
that this population was very carefully selected for its homogeneity,
only schizophrenia patients were included in the cohort, no
schizoaffective subjects were included. Additionally, extensive subject
demographics and medical histories were collected for all patients,
supporting the validity of this case–control cohort for this study. After
complete description of the study to the subjects, written informed con-
sent was obtained. This study was approved by and conducted accord-
ing to the guidelines of the University of Wollongong Human Research
Ethics Committee (HE 10/161).
2.2. SNP genotyping
SNPs within the NgR (rs701427, rs701428 and rs696880), p75
(rs1061622), TROY (rs9317882), WNK1 (rs1012729, rs12828016 and
rs1468326), and Myt1l genes (rs2304008, rs3748988, rs4073540 and
rs7592630) were tested in the Caucasian case–control schizophrenia
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sociations with schizophrenia and/or other disorders, and on their
Minor Allele Frequencies (MAF) reported in Caucasian populations
(MAF N 10%). High-throughput SNP genotyping was performed using
the MassARRAY® genotyping assay (Sequenom, Inc., San Diego, CA),
with the analysis performed by matrix-assisted laser desorption/
ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS). PCR
and extension primer design, selection and multiplexing were per-
formed using MassARRAY® Designer Software (Sequenom, Inc., San
Diego, CA). Control samples were run in parallel with the case–control
population, allowing for accurate evaluation and quality control checks
of each of the steps involved (PCR ampliﬁcation, Shrimp Alkaline
Phosphatase (SAP) treatment, extension PCR, nano-dropping to check
product concentrations, nano-dispensing of samples onto the chip,
and instrument performance). Additionally, only samples which had a
call rate of ≥80% were included in the analysis for this study. Any sam-
ples yielding less than 80% were omitted from the analysis steps.
2.3. Statistical analysis
The distribution of all of the tested SNPs did not deviate signiﬁcantly
from theHardy–Weinberg Equilibrium (HWE) (p N 0.05) except forNgR
rs701428, (p = 2.34 × 10−13) which was then excluded from further
analysis. To detect associations between each SNP and schizophrenia,
chi-square (χ2) analysis was performed to test for signiﬁcant differ-
ences in allele and genotype frequencies between the case and control
groups. The signiﬁcance for all statistical tests was set to p b 0.05. Data
are expressed as speciﬁc counts for alleles and genotypes. Bonferroni
correction was utilized to adjust for multiple comparisons in the SNP
analysis resulting in a corrected signiﬁcance level of p b 0.004 to give a
95% probability of correctly concluding not to reject the null hypothesis
in the χ2 test.
3. Results
Two SNPs within NgR, one SNP within p75 and TROY, three SNPs
withinWNK1 and four SNPs within theMyt1l genes were analyzed for
association with schizophrenia in a large Caucasian population (268
schizophrenia patients versus 268matched controls with no prior histo-
ry of psychiatric disorders).Table 2
Distribution of NgR genetic markers in schizophrenia subjects (n= 268) and controls (n= 26
N Alleles
NgR SNP Group Numbers (alleles)
rs696880
A
Schizophrenia 161 322 162 (50.3%)
Male 119 238 115 (48.3%)
Female 42 84 47 (56%)
Control 215 430 231 (53.7%)
Male 141 282 145 (51.4%)
Female 74 148 86 (58.1%)
Total case vs. control χ2 = 0.86
Male case vs. control χ2 = 0.50
Female case vs. control χ2 = 0.10
N Alleles
NgR SNP Group Numbers (alleles)
rs701427
C
Schizophrenia 169 338 258 (76.3%)
Male 123 246 185 (75.2%)
Female 46 92 73 (79.3%)
Control 207 414 295 (71.3%)
Male 133 266 187 (70.3%)
Female 74 148 108 (73%)
Total case vs. control χ2 = 2.46
Male case vs. control χ2 = 1.55
Female case vs. control χ2 = 1.24Analysis revealed that therewere no signiﬁcant associations between
any of the allelic frequencies of any of the tested SNPs (NgR rs701427
and rs696880, p75 rs1061622, TROY rs9317882, WNK1 rs1012729,
rs12828016 and rs1468326, and Myt1l rs2304008, rs3748988,
rs4073540 and rs7592630) and schizophrenia (0.10 ≤ p ≤ 0.95;
Tables 2, 3, 4 and 5). Additionally, none of the tested SNPs showed any
signiﬁcant genotypic associations with schizophrenia (0.10 ≤ p ≤ 0.99;
Tables 2, 3, 4 and 5).
Further, analysis of each of the genetic markers by gender revealed
that the rs2304008 SNP within theMyt1l gene had a signiﬁcant geno-
typic but not allelic associationwhen comparing the female schizophre-
nia subjects to the female control subjects only (p = 0.04; Table 5).
None of the remaining genetic markers showed any signiﬁcant allelic
or genotypic associations with gender (0.08 ≤ p ≤ 0.98; Tables 2, 3, 4
and 5). However after Bonferroni correction the signiﬁcance of the
Myt1l genotypic association in female schizophrenia subjects was lost.
It was interesting to note that our tested population demographics
revealed that a large percentage of our schizophrenia subjects, twice
as many as the control group, had a family history of mental disorders
(either mother, father or both parents), or experienced some sort of
trauma or adversity during their childhood (Table 1). χ2 analysis re-
vealed that theWNK1 rs1468326 SNP had a signiﬁcant allelic and geno-
typic association with schizophrenia in those subjects who had a
mother with a history of mental disorders (5.82 ≥ χ2 ≥ 6.38,
0.01 ≥ p ≥ 0.04; Table 6). In subjects who experienced some sort of
adversity during childhood, there was a signiﬁcant genotypic but not
allelic association with schizophrenia for the Myt1l SNP rs3748988
(χ2 = 7.72, p = 0.02; Table 6). None of the other tested SNPs in any
of the genes displayed any signiﬁcance when analyzed according to a
family history of mental disorders or traumatic childhood (p N 0.05).
Again, following Bonferroni correction for multiple testing, signiﬁcance
for the allelic and genotypicWNK1 associations in schizophrenia sub-
jects with a maternal history of mental disorders, and the genotypic
Myt1l association with schizophrenia in subjects who experienced
childhood trauma was lost.
4. Discussion
The present study examined the implication of genetic variants in
the NgR gene and its signaling co-factors (p75 and TROY) and genes8).
Genotypes
G AA AG GG
160 (49.7%) 38 (23.6%) 86 (53.4%) 37 (23%)
123 (51.7%) 27 (22.7%) 61 (51.3%) 31 (26%)
37 (44%) 11 (26.2%) 25 (59.5%) 6 (14.3%)
199 (46.3%) 68 (31.6%) 95 (44.2%) 52 (24.2%)
137 (48.6%) 41 (29.1%) 63 (44.7%) 37 (26.2%)
62 (41.9%) 27 (36.5%) 32 (43.2%) 15 (20.3%)
p= 0.35 χ2 = 3.79 p= 0.15
p= 0.48 χ2 = 1.59 p= 0.45
p= 0.74 χ2 = 2.84 p= 0.24
Genotypes
A CC CA AA
80 (23.6%) 99 (58.6%) 60 (35.5%) 10 (5.9%)
61 (24.8%) 69 (56.1%) 47 (38.2%) 7 (5.7%)
19 (20.7%) 30 (65.2%) 13 (28.3%) 3 (6.5%)
119 (28.7%) 105 (50.7%) 85 (41.1%) 17 (8.2%)
79 (29.7%) 67 (50.4%) 53 (39.8%) 13 (9.8%)
40 (27%) 38 (51.4%) 32 (43.2%) 4 (5.4%)
p= 0.11 χ2 = 2.49 p= 0.28
p= 0.21 χ2 = 1.80 p= 0.41
p= 0.26 χ2 = 2.72 p= 0.25
Table 3
Distribution of the p75 and TROY genetic markers in schizophrenia subjects (n= 268) and controls (n= 268).
N Alleles Genotypes
p75 SNP Group Numbers (alleles)
rs1061622
T G TT TG GG
Schizophrenia 142 284 202 (71.1%) 82 (28.9%) 68 (47.9%) 66 (46.5%) 8 (5.6%)
Male 100 200 149 (74.5%) 51 (25.5%) 52 (52%) 45 (45%) 3 (3%)
Female 42 84 53 (63.1%) 31 (36.9%) 16 (38.1%) 21 (50%) 5 (11.9%)
Control 195 390 298 (76.4%) 92 (23.6%) 111 (56.9%) 76 (39%) 8 (4.1%)
Male 124 248 194 (78.2%) 54 (21.8%) 75 (60.5%) 44 (35.5%) 5 (4%)
Female 71 142 104 (73.2%) 38 (26.8%) 36 (50.7%) 32 (45.1%) 3 (4.2%)
Total case vs. control χ2 = 2.40 p= 0.12 χ2 = 2.77 p= 0.25
Male case vs. control χ2 = 0.86 p= 0.35 χ2 = 2.13 p= 0.34
Female case vs. control χ2 = 2.56 p= 0.10 χ2 = 3.25 p= 0.19
N Alleles Genotypes
TROY SNP Group Numbers (alleles)
rs9317882
T C TT TC CC
Schizophrenia 186 372 256 (68.8%) 116(31.2%) 92 (49.5%) 72 (38.7%) 22 (11.8%)
Male 132 264 179 (67.8%) 85 (32.2%) 63(47.7%) 53 (40.2%) 16 (12.1%)
Female 54 108 77 (71.3%) 31 (28.7%) 29 (53.7%) 19 (35.2%) 6 (11.1%)
Control 171 342 253 (74.0%) 89 (26.0%) 97 (56.8%) 59 (34.5%) 15 (8.7%)
Male 113 226 169 (74.8%) 57 (25.2%) 65 (57.5%) 39 (34.5%) 9 (8.0%)
Female 58 116 84 (72.4%) 32 (27.6%) 32 (55.2%) 20 (34.5%) 6 (10.3%)
Total case vs. control χ2 = 2.32 p= 0.12 χ2 = 2.12 p= 0.34
Male case vs. control χ2 = 2.88 p= 0.08 χ2 = 2.66 p= 0.26
Female case vs. control χ2 = 0.03 p= 0.85 χ2 = 0.03 p= 0.98
Table 4
Distribution ofWNK1 genetic markers in schizophrenia subjects (n= 268) and controls (n= 268).
N Alleles Genotypes
WNK1 SNP Group Numbers (alleles)
rs1012729
A G AA AG GG
Schizophrenia 224 448 338 (75.4%) 110 (24.6%) 130 (58%) 78 (34.8%) 16 (7.1%)
Male 155 310 239 (77%) 71 (23%) 93 (60%) 53 (34.1%) 9 (5.8%)
Female 69 138 99 (71.7%) 392 (28.3%) 37 (53.6%) 25 (36.2%) 7 (10.1%)
Control 234 468 352 (75.2%) 116 (24.8%) 133 (56.8%) 86 (36.7%) 15 (6.4%)
Male 154 308 234 (76%) 74 (24%) 91 (59.2%) 52 (33.7%) 11 (7.1%)
Female 80 160 118 (73.8%) 42 (26.2%) 42 (52.5%) 34 (42.5%) 4 (5.0%)
Total case vs. control χ2 = 0.01 p= 0.93 χ2 = 0.24 p= 0.88
Male case vs. control χ2 = 0.11 p= 0.74 χ2 = 0.23 p= 0.89
Female case vs. control χ2 = 0.15 p= 0.69 χ2 = 1.70 p= 0.42
N Alleles Genotypes
WNK1 SNP Group Numbers (alleles)
rs12828016
G T GG GT TT
Schizophrenia 220 440 266 (60.5%) 174 (39.5%) 84 (38.1%) 98 (44.5%) 38 (17.2%)
Male 154 308 192 (62.3%) 116 (37.7%) 63 (40.9%) 66 (42.8%) 25 (16.2%)
Female 66 132 74 (56.1%) 58 (43.9%) 21 (31.8%) 32 (48.4%) 13 (19.6%)
Control 235 470 285 (60.6%) 185 (39.4%) 90 (382%) 105 (44.6%) 40 (17%)
Male 154 308 188 (61%) 120 (39%) 58 (37.6%) 72 (46.7%) 24 (15.5%)
Female 81 162 97 (60%) 65 (40%) 32 (39.5%) 33 (40.7%) 16 (19.7%)
Total case vs. control χ2 = 0.00 p= 0.95 χ2 = 0.01 p= 0.99
Male case vs. control χ2 = 0.11 p= 0.74 χ2 = 0.49 p= 0.78
Female case vs. control χ2 = 0.44 p= 0.50 χ2 = 1.09 p= 0.57
N Alleles Genotypes
WNK1 SNP Group Numbers (alleles)
rs1468326
C A CC CA AA
Schizophrenia 183 366 314 (85.7%) 52 (14.3%) 134 (73.2%) 46 (25.1%) 3 (1.6%)
Male 129 258 223 (86.4%) 35 (13.6%) 96 (74.4%) 31 (24%) 2 (1.5%)
Female 54 108 91 (84.3%) 17 (15.7%) 38 (70.3%) 15 (27.7%) 1 (1.8%)
Control 213 426 376 (88.3%) 50 (11.7%) 169 (79.3%) 38 (17.8%) 6 (2.8%)
Male 142 284 256 (90.1%) 28 (9.9%) 116 (81.6%) 24 (16.9%) 2 (1.4%)
Female 71 142 120 (84.5%) 22 (15.5%) 53 (74.6%) 14 (19.7%) 4 (5.6%)
Total case vs. control χ2 = 1.07 p= 0.30 χ2 = 3.55 p= 0.16
Male case vs. control χ2 = 1.81 p= 0.17 χ2 = 2.16 p= 0.33
Female case vs. control χ2 = 0.00 p= 0.95 χ2 = 2.03 p= 0.36
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Table 5
Distribution ofMyt1l genetic markers in schizophrenia subjects (n= 268) and controls (n= 268).
N Alleles Genotypes
Myt1l SNP Group Numbers (alleles)
rs2304008
A C AA AC CC
Schizophrenia 193 386 261 (67.6%) 125 (32.3%) 93 (48.1%) 75 (39.1%) 25 (12.9%)
Male 134 268 180 (67.2%) 88 (32.8%) 61 (45.5%) 58 (43.2%) 15 (11.1%)
Female 59 118 81 (68.6%) 37 (31.4%) 32 (54.2%) 17 (28.8%) 10 (16.9%)
Control 222 444 323 (72.7%) 121 (273%) 116 (52.2%) 91 (40.9%) 15 (6.7%)
Male 147 294 213 (72.4%) 81 (27.6%) 77 (52.3%) 59 (40.1%) 11 (7.4%)
Female 75 150 110 (73.3%) 40 (26.7%) 39 (52%) 32 (42.6%) 4 (5.3%)
Total case vs. control χ2 = 2.61 p= 0.10 χ2 = 4.57 p= 0.10
Male case vs. control χ2 = 1.86 p= 0.17 χ2 = 1.58 p= 0.39
Female case vs. control χ2 = 0.71 p= 0.39 χ2 = 6.03 p= 0.04
N Alleles Genotypes
Myt1l SNP Group Numbers (alleles)
rs3748988
A G AA AG GG
Schizophrenia 225 450 298 (66.2%) 152 (33.7%) 105 (46.6%) 88 (39.1%) 32 (14.2%)
Male 156 312 214 (68.6%) 98 (31.4%) 77 (49.3%) 60 (38.4%) 19 (12.1%)
Female 69 138 84 (60.8%) 54 (39.2%) 28 (40.5%) 28 (40.5%) 13 (18.8%)
Control 235 470 299 (63.6%) 171 (36.4%) 93 (39.5%) 113 (48%) 29 (12.3%)
Male 154 308 198 (64.3%) 110 (35.7%) 65 (42.2%) 68 (44.1%) 21 (13.6%)
Female 81 162 101 (62.3%) 61 (37.7%) 28 (34.5%) 45 (55.5%) 8 (9.8%)
Total case vs. control χ2 = 0.68 p= 0.40 χ2 = 3.77 p= 0.15
Male case vs. control χ2 = 1.29 p= 0.25 χ2 = 1.60 p= 0.44
Female case vs. control χ2 = 0.07 p= 0.79 χ2 = 4.22 p= 0.12
N Alleles Genotypes
Myt1l SNP Group Numbers (alleles)
rs4073540
A C AA AC CC
Schizophrenia 234 468 280 (60%) 188 (40%) 80 (34.1%) 120 (51.2%) 34 (14.5%)
Male 160 320 193 (60.3%) 127 (39.7%) 54 (33.7%) 85 (53.1%) 21 (13.1%)
Female 74 148 87 (58.8%) 61 (41.2%) 26 (35.1%) 35 (47.2%) 13 (17.5%)
Control 238 476 292 (61.3%) 184 (38.7%) 83 (34.8%) 126 (52.9%) 29 (12.1%)
Male 156 312 189 (60.3%) 123 (39.4%) 52 (33.3%) 85 (54.4%) 19 (12.1%)
Female 82 164 103 (62.8%) 61 (37.2%) 31 (37.8%) 41 (50%) 10 (12.1%)
Total case vs. control χ2 = 0.23 p= 0.63 χ2 = 0.56 p= 0.75
Male case vs. control χ2 = 0.00 p= 0.94 χ2 = 0.09 p= 0.95
Female case vs. control χ2 = 0.53 p= 0.46 χ2 = 0.90 p= 0.63
N Alleles Genotypes
Myt1l SNP Group Numbers (alleles)
rs7592630
T C TT TC CC
Schizophrenia 226 452 293 (64.8%) 159 (35.2%) 95 (42%) 103 (45.5%) 28 (12.3%)
Male 157 314 213 (67.3%) 101 (32.2%) 72 (45.8%) 69 (43.9%) 16 (10.1%)
Female 69 138 80 (58.9%) 58 (42%) 23 (33.3%) 34 (49.2%) 12 (17.3%)
Control 236 472 294 (62.3%) 178 (37.7%) 90 (38.1%) 114 (48.3%) 32 (13.5%)
Male 155 310 194 (62.6%) 116 (37.4%) 61 (39.4%) 72 (46.4%) 22 (14.2%)
Female 81 162 100 (61.7%) 62 (38.3%) 29 (35.8%) 42 (51.8%) 10 (12.3%)
Total case vs. control χ2 = 0.64 p= 0.42 χ2 = 0.74 p= 0.68
Male case vs. control χ2 = 1.90 p= 0.16 χ2 = 1.91 p= 0.38
Female case vs. control χ2 = 0.44 p= 0.50 χ2 = 0.76 p= 0.68
Signiﬁcant associations are shown in bold.
40 J.L. Andrews, F. Fernandez-Enright / BBA Clinical 3 (2015) 36–43encoding for its downstream signalingmolecules (WNK1 andMyt1l), in
an Australian Caucasian schizophrenia case–control population, taking
early life adversities into consideration.
NgRmutations are presentwithin 1–2% of the schizophrenia popula-
tion [6,9,21]. It has been reported that deletion mutations within the
chromosomic region 22q11 (including the NgR locus), have an associa-
tion with a risk of schizophrenia 25 times greater than the general pop-
ulation [22,23]. This makes the 22q11 deletion mutation one of the
strongest known genetic risk factors for schizophrenia [24,25]. The
NgR SNP rs701428 was found in the present study to lie outside HWE,
meaning it could not be included in our analysis. However, rs701428
is located near the 3′ end of the gene, and Liu et al. have provided evi-
dence to suggest that common NgR variants located at the 3′ end of
NgR gene are associated with schizophrenia in North American popula-
tions [23] which supports our hypothesis for including this marker in
our study, despite our lack of association found. Association of SNPs inthe NgR gene with schizophrenia has previously been found in various
Caucasian populations [9,23], but not in Chinese [26] and Japanese pop-
ulations [27], with only a weak association found in Afrikaners [28].
While the present study did not ﬁnd any signiﬁcant associations with
schizophrenia and either of our investigated intronic NgR SNPs,
rs701427 and rs696880 which have been examined in other schizo-
phrenia populations [9], several rare coding variants of NgR (R119W,
R196H, L18L, R377W, R227C and R399W) have been previously found
in patients with schizophrenia [6,9]. Subjects expressing R377Q,
R377W, R119W and R196H were shown to have an inhibition of
signal transduction of NgR by its oligodendrocyte-bound ligands in
coimmunoprecipitation and ligand binding experiments [6,9]. Genetic
mutations in the NgR gene could therefore be involved in the stabiliza-
tion of neuronal wiring in the development of the schizophrenia brain.
Interestingly, R119W and R196H were found in patients who displayed
predominantly negative symptoms which were strongly resistant to
Table 6
Allelic and genotypic distributions forWNK1 andMyt1l geneticmarkers in schizophrenia subjects and controlswith respect to parental history ofmental health issues and traumatic child-
hood experiences.
WNK1 Alleles Genotypes
rs1468326 Group Numbers C A CC CA AA
Schizophrenia 183 314 (85.8%) 52 (14.2%) 134(73.2%) 46(25.1%) 3(1.6%)
Mother mental history 65 106 (81.5%) 24 (18.5%) 42 (64.6%) 22 (33.8%) 1 (1.5%)
Father mental history 75 130 (86.7%) 20 (13.3%) 56 (74.7%) 18 (24.0%) 1 (1.3%)
Traumatic childhood 76 131 (86.2%) 21 (13.8%) 55 (72.4%) 21 (27.6%) 0 (0.0%)
Control 213 376 (88.3%) 50 (11.7%) 169(79.3%) 38(17.8%) 6(2.8%)
Mother mental history 34 64 (94.1%) 4 (5.9%) 30 (88.2%) 4 (11.8%) 0 (0.0%)
Father mental history 39 71 (91.0%) 7 (9.0%) 33 (84.6%) 5 (12.8%) 1 (2.6%)
Traumatic childhood 43 74 (86.0%) 12 (14.0%) 33(76.7%) 8 (18.6%) 2 (4.7%)
Mother mental case vs. control χ2 = 5.82 p= 0.01 χ2 = 6.38 p= 0.04
Father mental case vs. control χ2 = 0.93 p= 0.34 χ2 = 2.13 p= 0.34
Traumatic childhood case vs. control χ2 = 0.00 p= 0.97 χ2 = 4.52 p= 0.10
Myt1l Alleles Genotypes
rs3748988 Group Numbers C A AA AG GG
Schizophrenia 225 298 (66.2%) 152 (33.8%) 105(46.6%) 88(39.1%) 32(14.2%)
Mother mental history 76 92 (60.5%) 60 (39.5%) 28 (36.8%) 36 (47.4%) 12 (15.8%)
Father mental history 87 103 (59.2%) 71 (40.8%) 33 (37.9%) 37 (42.5%) 17 (19.5%)
Traumatic childhood 91 113 (62.1%) 69 (37.9%) 39 (42.9%) 35 (38.5%) 17 (18.7%)
Control 235 299 (63.6%) 171 (36.4%) 93(39.5%) 113(48%) 29(12.3%)
Mother mental history 40 47 (58.8%) 33 (41.3%) 12 (30.0%) 23 (57.5%) 5 (12.5%)
Father mental history 43 54 (62.8%) 32 (37.2%) 15 (34.9%) 24 (55.8%) 4 (9.3%)
Traumatic childhood 52 67 (64.4%) 37 (35.6%) 18 (34.6%) 31 (59.6%) 3 (5.8%)
Mother mental case vs. control χ2 = 0.07 p= 0.79 χ2χ2 = 1.08 p= 0.58
Father mental case vs. control χ2 = 0.31 p= 0.58 χ2 = 3.02 p= 0.22
Traumatic childhood case vs. control χ2 = 0.15 p= 0.69 χ2 = 7.72 p= 0.02
Signiﬁcant associations are shown in bold.
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both R119Wand R196Hmay play a role in affecting the binding interac-
tions between NgR protein and its ligands or with its co-receptors.
Analysis of genetic polymorphisms in both co-receptor and cofactor
p75 and TROY genes, did not display any signiﬁcant differencewithin the
tested SNPs of their respective genes in the schizophrenia sufferers com-
pared to their controls (p N 0.05). To our knowledge, no previous reports
have investigated the role of genetic polymorphisms in the p75 and
TROY genes in the susceptibility for schizophrenia however, our tested
SNP in the TROY gene has been previously implicated in the genetic vul-
nerability of another neurological disorder (vascular dementia [29]).
Changes in protein levels of both p75 andTROYhave been previously re-
ported in postmortem hippocampal regions from schizophrenia suf-
ferers compared to controls in two independent brain cohorts (Stanley
consortium brain cohort [30] and the New SouthWales Brain Bank Net-
work schizophrenia case–control cohort [31] respectively), supporting a
role of these two proteins in the pathophysiology of schizophrenia and
their potential as candidate genes in the susceptibility of schizophrenia.
Regarding the downstream partners of NgR, our tested SNPs in the
WNK1 and Myt1l genes were not associated with schizophrenia in our
population p N 0.05. We studied two intronic SNPs (rs4073540 and
rs7592630) located within the exon rich region located at the distal
part of theMyt1l gene, as well as two SNPs in exon 7 (rs2304008) and
exon 9 (rs3748988)within theMyt1l gene. None of these SNPswere as-
sociated with schizophrenia in our Caucasian population. However,
polymorphisms in theMyt1l gene have recently been reported to be as-
sociated with schizophrenia in a Chinese Han population, with one SNP
having an association with a family history of schizophrenia in females
[17]. Despite our results not having an overall signiﬁcant association
with schizophrenia, before Bonferroni correction our Myt1l SNP
rs2304008 had a signiﬁcant association in female schizophrenia sub-
jects compared to female controls. Our ﬁndings, in concert with those
found by Li et al., suggest that SNPs within the homologous Myt1 and
Myt1l genes may increase the susceptibility for schizophrenia in
females. Interestingly, theMyt1 genehas been shown to regulate the ex-
pression of the Neuregulin-1 (NRG1) gene, an extensively studiedschizophrenia candidate gene involved in myelination processes [32],
in schizophrenia patients [33] conﬁrming the potential for the suscepti-
bility of this gene in schizophrenia.
The expression of theWNK1 gene has been previously reported to be
upregulated in the postmortem prefrontal cortex from schizophrenia
sufferers [13,15], in addition to a recent report of an upregulation of
WNK1 protein expression in the hippocampus of schizophrenia suf-
ferers [31], thus triggering our initial interest to involve the gene of
this kinase in our study. Despite the consistently reported upregulation
of WNK1 in the prefrontal cortex of schizophrenia sufferers, no SNPs
were found to be signiﬁcantly associated with schizophrenia in the
same studies [13,15,34] thus supporting the lack of signiﬁcant ﬁndings
within theWNK1 gene in the present study.
The suppression ofWNK1 expression by RNA interference has been
shown to promote neurite extension and eliminate the inhibitory re-
sponse to Nogo signaling in cortical cultured neurons [35]. In addition,
the overexpression of WNK1 (123-510) reduces Nogo-induced inhibi-
tion of neurite extension rather than strengthening it, and inhibits the
activation of RhoA [35]. Previous studies have shown that WNK1 is a
negative regulator of cell growth via phosphorylation by the PI3-K/Akt
signaling pathway [36], which is largely implicated in the schizophrenia
pathophysiology. Furthermore, disruption of the WNK1 gene in mice
leads to death of the embryo at day 13 [23–25], suggesting an essential
role ofWNK1 in embryonic and neural development, which is a critical
period implicated in schizophrenia.
Whenwe factored a family history of psychiatric illness or traumatic
childhood experiences into our analysis;we found thatWNK1 andMyt1l
SNPs had signiﬁcant associations with schizophrenia in subjects with a
maternal mental history and childhood trauma respectively. These re-
sults suggest that the genes for the downstream signaling partners of
NgRmay play a role in the inheritance of psychiatric disorders. Further-
more, alterations in brain volumes [19,37,38] and abnormal axonal
connectivity, in particular within the corpus callosum (the highest my-
elinated ﬁber tract in the brain), have been observed in children with a
history of abuse or neglect [3,39–42]. The large majority of nerve ﬁber
connections passing through the corpus callosum are established before
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through this region continue into adolescence [43], which is a critical
period for the development of schizophrenia. Considering the role that
NgR and its co-factor signaling partners have inmyelin-related process-
es, and that a number of studies have shown strong associations
between negative childhood experiences and adult psychiatric illnesses
in addition to alterations in myelinated regions of the brain [19,44–46];
it seems reasonable to speculate that these genes may prove useful in
understanding the mechanism by which negative experiences early in
life can affect myelin-related processes in the context of schizophrenia.
5. Conclusions
Despite the fact that our study reported no signiﬁcant associations
after Bonferroni correction between any of the tested genetic markers
in any of our studied genes within NgR signaling pathways, there is
ample literature to support the hypothesis that NgR signaling is altered
in schizophrenia as highlighted by the involvement of these pathways
in neuronal growth, myelination and memory processes. Previous
studies have found alterations in these genes through gene expression
and genetic association studies in schizophrenia patients; and evidence
suggests a role for these genes inmyelin-related processes in psychiatric
disease. The characterization of the complete pathway involved in this
model remains to be a warranted avenue of research yet to be fully in-
vestigated in the pathogenesis of schizophrenia.
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